• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cue Health Appoints Nitin Duggal as Chief Marketing Officer

    12/16/21 9:15:00 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HLTH alert in real time by email

    SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Cue Health Inc. ("Cue") (NASDAQ:HLTH), a health technology company, today announced that it has appointed Nitin Duggal as its first Chief Marketing Officer, effective immediately. In his new role, he will be responsible for leading all marketing initiatives at Cue, including partners, direct to consumer, customers, employers, and providers.

    Nitin Duggal

    Nitin has over 15 years of executive experience at high-growth technology organizations in Silicon Valley. During his tenure, he has developed a proven track record of scaling innovative technology platforms, developing robust product portfolios and leading high-performance teams. Nitin joins Cue to help further strengthen the company's brand, marketing, and technology capabilities across its virtual care platform and products.

    "On behalf of everyone at Cue, I'm thrilled to welcome Nitin to Cue. Nitin brings a wealth of experience in developing product marketing strategies and building teams around consumer insights, which we expect will meaningfully contribute to our mission of empowering people to live their healthiest lives as Cue enters its next chapter of growth," said Ayub Khattak, co-founder and CEO of Cue.

    "I am honored to be part of the Cue family and excited to embark on a journey together that we believe will transform the consumer health experience. The COVID-19 pandemic has exposed the fragility of our healthcare system and Cue Health is uniquely positioned to offer innovative solutions that are already empowering more and more people to take control of their health. Together, we can bring meaningful change to the healthcare space," added Nitin Duggal.

    Nitin joins Cue from Abbott Diabetes Care, where he spent 10 years in a number of leadership positions. Most recently, he served as Senior Commercial Director in Abbott's Biowearables group to promote and commercialize sensing technology among the non-diabetic population. Nitin also established a digital health group in the U.S. to redefine the consumer journey and to explore alternate reimbursement models. Prior to that he launched a number of Libre® products in the U.S. market as Senior Marketing Director and served as marketing lead for the launch of FreeStyle® Libre in European markets.

    Prior to Abbott, Nitin was a consultant at McKinsey & Co and focused on the healthcare industry. During his stay at McKinsey, he led different engagements with payors and medical device companies. Nitin received his MBA degree from Tuck School of Business at Dartmouth and holds an undergraduate degree in Electronics and Electrical Communication.

    About Cue Health

    Cue Health (NASDAQ:HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organisation, and PSAR authorization from Singapore's Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

     

    (PRNewsfoto/Cue Health Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cue-health-appoints-nitin-duggal-as-chief-marketing-officer-301446437.html

    SOURCE Cue Health Inc.

    Get the next $HLTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLTH

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Health to Pursue Wind Down of the Business

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

      5/28/24 4:31:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

      Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

      5/13/24 8:30:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

      For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

      6/6/23 3:04:14 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials